Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients

Table 1 Patient characteristics

Group
Age, years (mean, SD)		60.9	11.2
Body mass index (mean, SD)		26.9	6.1
Tumor stage (n, %)	T1	18	30.0
	T2–4	40	66.6
	n.a.	2	3.3
N-staging (n, %)	N+	36	60.0
	N0	18	30.0
	n.a.	6	10.0
ER (n, %)	Positive	42	70.0
	Negative	17	28.3
	n.a.	1	1.7
PR (n, %)	Positive	38	63.3
	Negative	21	35.0
	n.a.	1	1.7
HER2 (n, %)	Positive	12	20.0
	Negative	41	68.3
	n.a.	7	11.7
Grading (n, %)	G1	4	6.7
	G2	27	45.0
	G3	28	46.7
	n.a.	1	1.7
Histopathological subtype (n, %)	Ductal	50	83.3
	Lobular	7	11.7
	Others	2	3.4
	n.a.	1	1.7
Treatment line^a (n, %)	First line	16	26.7
	Second line	12	20.0
	Third line	12	20.0
	Higher	18	30.0
	n.a.	2	3.3
Treatment at blood draw (n, %)	Chemotherapy	27	45.0
Treatment at blood draw (n, %)	AH	18	30.0
	Others^b	42	70.0

^aTherapy lines are either chemotherapies, antihormone therapies or other anti-cancer treatments. Each initiated therapy line is counted as one regardless of whether a disease progression triggered the therapy initiation
^be.g. bone modifying drugs or monoclonal antibodies

ISSN: 1471-2407